• Boehringer Ingelheim GmbH, of Ingelheim, Germany, reported findings at the Asia Pacific Stroke Conference in Tokyo, confirming that, in Asian populations, Pradaxa (dabigatran etexilate) offered considerable benefits for the management of patients with atrial fibrillation. Read More
• H. Lundbeck A/S, of Copenhagen, Denmark, said the FDA accepted a resubmission of a new drug application by for aripiprazole depot formulation, which is in development for schizophrenia. Read More
• e-Therapeutics plc, of Oxford, UK, said it started a second Phase I trial testing cancer drug ETS2101, a drug designed to promote apoptosis. The dose-escalating study is expected to enroll up to 45 patients with a variety of solid tumors. Read More
• Edison Pharmaceuticals Inc., of Mountain View, Calif., said the European Medicines Agency's Committee for Orphan Medicinal Products granted orphan designation to EPI-743 for the treatment of Leigh syndrome. Read More
A slew of recent failures in Alzheimer's disease (AD) could prove providential for NeuroNascent Inc., which has ambitious plans to halt and potentially reverse a range of neurodegenerative diseases. Read More
Novel analyses of the RV144 HIV vaccine trial, also known as the Thai trial, have analyzed viral variants that were able to get past the protection the vaccine offered. Those results, published in Nature and presented at the AIDS Vaccine 2012 conference this week, add to the emerging understanding that targeting certain parts of HIV's envelope protein is likely the best path to an effective vaccine. Read More
